BBL
CRSP icon

Beck Bode LLC’s CRISPR Therapeutics CRSP Stock Holding History

Beck Bode LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-98,801
Closed -$5.18M – 114
2025
Q4 		$5.18M Buy
+98,801
New +$5.92M 0.86% 38

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Beck Bode LLC's CRSP Position: Q1 2026 in Review

Beck Bode LLC sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 98,801 shares — an estimated $5.18M sold.

Beck Bode LLC first reported a position in CRSP in Q4 2025 and held it in 1 quarter. The position peaked at $5.18M in Q4 2025. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Beck Bode LLC reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Beck Bode LLC sold 98,801 CRISPR Therapeutics shares in Q1 2026, an estimated $5.18M.
  • Beck Bode LLC first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 1 quarter.
  • Beck Bode LLC's CRISPR Therapeutics position peaked at $5.18M in Q4 2025.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Beck Bode LLC's 13F filing for Q1 2026, filed 7 May 2026.